Skip to content
Drix10 Blog

lenacapavir generic FDA approval $40 per year

, 8 items in Neuroscience and AI, 4 min read

In this digest (8 items)

lenacapavir generic injectable approved by FDA; protects from HIV for 6 months and will be sold for $40 per person per year.

Key points

  • FDA approval of generic injectable lenacapavir

  • Pricing pledged at $40 per person per year

  • Protection duration of 6 months per dose

  • Manufacturer Dr. Reddy’s Laboratories will market the drug​

Sources

Martian meteorite - formed 4.1 billion years ago

Martian meteorite found in the Sahara Desert formed at least 4.1 billion years ago, providing a sample of Mars’ early crust. New study published in Science reports this result.

Key points

  • Location: Sahara Desert

  • Age: at least 4.1 billion years, sample of early Martian crust

Sources

Azetukalner reduces focal seizure frequency in adults

Azetukalner reduced seizure frequency versus placebo in adults with focal epilepsy who had ongoing focal seizures despite 1-3 antiseizure meds, showing rapid and durable benefit over a 12-week double-blind period. The result comes from a trial of patients with continued focal seizures.

Key points

  • Reduced seizure frequency vs placebo in adults with focal epilepsy.

  • Benefit was rapid and durable during the 12-week double-blind period.

Sources

Castration extends male mouse lifespan by over 30%

Castration extends male mouse lifespan by over 30% when performed on older mice. Researchers report neutering older male mice lengthens their lives by more than 30%, upending prior assumptions about timing.

Key points

  • Removing the testicles extends male life span across many mammalian species, including humans.

  • Neutering older male mice lengthens their lives by more than 30%.

Sources

hair analysis yields earliest direct evidence of psychoactive cannabis

hair analysis of a 2800-year-old tomb provides the earliest direct evidence of psychoactive cannabis use. Findings appear in Science and discuss the plant’s role in ancient societies.

Key points

  • 2800-year-old tomb hair analysis

  • earliest direct evidence of psychoactive cannabis use

Sources

RIMKLA-IgG identified as biomarker for paraneoplastic syndrome

RIMKLA-IgG identified as a new biomarker of paraneoplastic neurological syndrome with cerebellar ataxia, hindbrain encephalitis, inflammatory cerebrospinal fluid, and frequent Small Cell Lung Cancer. The syndrome includes cerebellar ataxia and hindbrain encephalitis.

Key points

  • RIMKLA-IgG identified as new biomarker of paraneoplastic neurological syndrome

  • Associated with cerebellar ataxia, hindbrain encephalitis, inflammatory cerebrospinal fluid, and frequent Small Cell Lung Cancer

Sources

CD19 ChimericAntigenReceptor T-cell therapy single dose improves mobility

CD19 ChimericAntigenReceptor T-cell therapy for Stiff Person Syndrome was given as a single dose and showed clinically meaningful mobility improvement. The treatment also showed changes supportive of immune reset and had a manageable safety profile.

Key points

  • Single dose associated with clinically meaningful mobility improvement

  • Changes supportive of immune reset observed

  • Manageable safety profile reported

Sources

ScienceMagazine GLP-1 and Beyond special issue review

ScienceMagazine GLP-1 and Beyond special issue includes a Review on obesity pharmacotherapies and cognition. The review explores potential effects on brain health and outlines remaining questions.

Key points

  • Special issue of ScienceMagazine on “GLP-1 and Beyond” is out this week.

  • Contributed a Review on obesity pharmacotherapies and cognition.

Sources